FD268, a representative of the pan-PI3K inhibitor candidate developed subsequently, was proven to inhibit the PI3K/AKT/mTOR signaling pathway and exhibited high antiproliferative effects against AML cells [31]. This evidence concerns the gene AKT1 and acute myeloid leukemia.